Clinical trial
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate…
NCT00293371 · University of California, San Francisco, Other · Terminated
Key facts
| NCT number | NCT00293371 |
|---|---|
| Title | Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer |
| Official title | A Phase I/II Study of Docetaxel/Prednisone and PTK 787/ZK 222584 in Previously Untreated Metastatic Hormone Refractory Prostate Cancer |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, prednisone, vatalanib |
| Enrollment | 6 |
| Start date | Feb 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Feb 17, 2006 |
| Last update posted | Oct 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: